ASX Announcement

29 May 2023

USPTO allows new TPM manufacturing patent with protection to 2037

Highlights:

- The USPTO has allowed a new patent covering an optimized manufacturing method for TPM®.
- The US patent will protect TPM manufacturing until 2037 or later.
- The new TPM patent has already been granted in India, Japan, Mexico, Russia and Singapore.
- Further patents, specific to the combination of TPM with cannabinoids, are under review in various territories.

Melbourne, Australia, 29 May 2023: Avecho Biotechnology Limited (ASX:AVE, "Avecho", or "the Company") has today announced that the US Patent and Trade Marks Office ("USPTO") has allowed its new patent application directed to an optimized manufacturing process for TPM®.

TPM is the core technology underpinning all of Avecho's product development activities. It has been shown to increase the solubility, stability, and absorption of a range of pharmaceutical and nutraceutical molecules and is the key ingredient in Vital-ET, Avecho's personal care ingredient distributed by Ashland world-wide.

Avecho's optimized TPM manufacturing method provides TPM with higher purity at greater yields, thus enabling Avecho to provide for Avecho's current and future product development activities, including new product activities with improved cost effectiveness and process efficiencies. In this context, the allowance of Avecho's US patent application is a significant commercial outcome.

When granted, the US patent is expected to provide Avecho with monopoly rights Avecho's TPM manufacturing process until about December 2037 or later.

This development follows the recent grant of patent rights to the manufacturing process in India, Japan, Mexico, Russia, and Singapore, and foreshadows a pathway to grant in the remaining jurisdictions where Avecho patent applications covering the manufacturing process are pending.

Avecho CEO, Dr Paul Gavin, said: *"Avecho has established a large patent portfolio protecting all candidate applications of our TPM. However, the core intellectual property has always been the patent protecting the manufacture of TPM. With this new patent, allowed in the largest pharmaceutical market in the world, we have ensured our ability to protect our technology and products that contain the technology, well into the future. This extended patent protection is timely given the new products under development combining TPM formulations with cannabinoids."*

Avecho's current patent portfolio contains over 10 patent families protecting a range of applications for TPM. Although already protected by existing patents, new families have been filed to protect the specific combination of TPM with cannabinoids to produce increased absorption. These patents have progressed through PCT stage and have now been filed in a number of different countries.

- ENDS -

This announcement is authorised for release by the Board of Directors of Avecho Biotechnology Limited.

Questions related to the announcement are welcome via our InvestorHub platform.

Investor + General Enquiries

Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - avecho.com.au.

Forward-Looking Statements

Certain statements in this announcement are forward looking statements. Forward-looking statements can generally be identified by the use of words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "may", "assume" and words of similar import. These forward-looking statements speak only as at the date of this announcement. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Avecho that the forward-looking statements contained in this announcement are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Avecho and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this announcement or any error or omission therefrom.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Avecho since the date of the announcement.